EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma

Fredrik Schjesvold iD, Andrew Spencer, Yael C Cohen, Enrique M Ocio, Jordi Lopez-Pardo, Anna Maria Cafro, Natalie S Callander, Jonathan L Kaufman, Meera Mohan iD, Martin Wermke, Noriko Doki, Rebecca Kan und 11 weitere

Cancer · 01.04.2026 · 132 (7)

DOI: 10.1002/cncr.70341 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, online erschienen am 25.03.2026. Verfasst von Fredrik Schjesvold und 22 weiteren Autor:innen. Beteiligte Einrichtung: Oslo Myeloma Center, Department of Hematology, OSLO University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Amyloid Precursor Protein Secretases, B-Cell Maturation Antigen. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This first‐in‐human phase 1 study evaluated the B‐cell maturation antigen (BCMA)×CD3 bispecific antibody WVT078 alone and in combination with the γ‐secretase inhibitor WHG626 in patients with relapsed/refractory multiple myeloma (r/r MM).

Method

The primary objectives were to assess safety, tolerability, and to determine the recommended doses (RDs) and regimens for expansion for WVT078 and WHG626. Secondary objectives included the assessment of preliminary antitumor activity and characterization of pharmacokinetics and immunogenicity.

Result

Overall, 56 patients were treated in the dose‐escalation part of the study, seven of whom experienced dose‐limiting toxicities. Across all dose levels, cytokine release syndrome was the most common treatment‐related adverse event. WVT078 monotherapy showed an overall response rate (ORR) of 27.3% and a complete response rate (CRR) of 12.1%. WVT078 combined with WHG626 demonstrated an ORR of 47.8% and a CRR of 21.7%. RDs were not declared, and dose expansion was not initiated.

Conclusion

WVT078 administered with and without WHG626 showed a manageable safety profile. Preliminary activity was observed in patients with r/r MM. The addition of WHG626 numerically improved response over WVT078 monotherapy. Findings from this study support further evaluation of WHG626 as a combination partner of BCMA‐targeting agents for r/r MM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificAmyloid Precursor Protein SecretasesB-Cell Maturation AntigenAntineoplastic Combined Chemotherapy ProtocolsHumansMiddle AgedFemaleAgedMaleAdultNeoplasm Recurrence, LocalCD3 ComplexAged, 80 and overMaximum Tolerated DoseDose-Response Relationship, Drug

Stichwörter der Autor:innen

BCMA×CD3 bispecific antibodyWHG626WVT078combination therapydose‐escalation studyrelapsed and/or refractory multiple myelomaγ‐secretase inhibitor

Substanzen

Antibodies, BispecificAmyloid Precursor Protein SecretasesB-Cell Maturation AntigenCD3 ComplexTNFRSF17 protein, human

Autor:innen und Institutionen

  • Oslo Myeloma Center, Department of Hematology, OSLO University Hospital, Oslo, Norway.
  • KG Jebsen Center for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • The Alfred Hospital, Monash University, Melbourne, Victoria, Australia.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Hospital Universitario Marqués de Valdecilla, Idival, Santander, Spain.

ORCID-Profile: Fredrik Schjesvold, Meera Mohan, Pedro Milanez-Almeida, Clinton Lai

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Schjesvold, F., Spencer, A., Cohen, Y. C., Ocio, E. M., Lopez-Pardo, J., Cafro, A. M., Callander, N. S., Kaufman, J. L., Mohan, M., Wermke, M., Doki, N., Kan, R., Milanez-Almeida, P., Stein, A., Trabucco, G., Ye, S., Kulec, K., Sechaud, R., Banerjee, S., …, & Raab, M. S. (2026). Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma. Cancer, 132(7). https://doi.org/10.1002/cncr.70341

Vancouver

Schjesvold F, Spencer A, Cohen YC, Ocio EM, Lopez-Pardo J, Cafro AM, et al. Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma. Cancer. 2026;132(7). doi:10.1002/cncr.70341

BibTeX
@article{Schjesvold2026,
  author = {Schjesvold, Fredrik and Spencer, Andrew and Cohen, Yael C and Ocio, Enrique M and Lopez-Pardo, Jordi and Cafro, Anna Maria and Callander, Natalie S and Kaufman, Jonathan L and Mohan, Meera and Wermke, Martin and Doki, Noriko and Kan, Rebecca and Milanez-Almeida, Pedro and Stein, Andrew and Trabucco, Gina and Ye, Stan and Kulec, Karolina and Sechaud, Romain and Banerjee, Souvik and Zhong, Huiqin and Lai, Clinton and Rauch, Philipp J and Raab, Marc S},
  title = {Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {7},
  doi = {10.1002/cncr.70341}
}
Kostenlos starten →